Tokyo - Delayed Quote JPY

Nippon Shinyaku Co., Ltd. (4516.T)

3,340.00 -133.00 (-3.83%)

At close: November 6 at 3:30:00 PM GMT+9

Chart Range Bar

Loading chart for 4516.T

Previous Close 3,473.00
Open 3,345.00
Bid 3,322.00 x --
Ask 3,343.00 x --
Day's Range 3,302.00 - 3,374.00
52 Week Range 3,261.00 - 6,529.00
Volume 605,700
Avg. Volume 397,293
Market Cap (intraday) 225.119B
Beta (5Y Monthly) --
PE Ratio (TTM) 7.13
EPS (TTM) 468.46
Earnings Date Nov 13, 2026
Forward Dividend & Yield 124.00 (3.71%)
1y Target Est 3,406.25
Moby Rating Neutral

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc. to develop ATSN-101 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and Regenex Bio Inc. to develop RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis type I and II. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

www.nippon-shinyaku.co.jp

2,309

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4516.T

39.12%

Nikkei 225 (^N225)

14.09%

1-Year Return

4516.T

6.59%

Nikkei 225 (^N225)

12.87%

3-Year Return

4516.T

36.75%

Nikkei 225 (^N225)

75.60%

5-Year Return

4516.T

59.48%

Nikkei 225 (^N225)

93.96%

Earnings Per Share (GAAP)

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q1 FY27

Revenue 49.07B

Earnings 10.11B

Profit Margin 20.60%

FY26

FY27

10B

20B

30B

40B

10.0%

12.0%

14.0%

16.0%

18.0%

20.0%

Analyst Price Targets

2,800.00 Low

3,406.25 Average

3,340.00 Current

4,200.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

17.51%
Return on Assets (ttm)

6.93%
Return on Equity (ttm)

11.54%
Revenue (ttm)

180.29B
Net Income Avi to Common (ttm)

31.56B
Diluted EPS (ttm)

468.46

Balance Sheet and Cash Flow

Total Cash (mrq)

72.7B
Total Debt/Equity (mrq)

0.87%
Levered Free Cash Flow (ttm)

19.74B

4528.T Ono Pharmaceutical Co., Ltd.

2,352.50 -5.48%

4507.T Shionogi & Co., Ltd.

2,981.50 -6.59%

4506.T Sumitomo Pharma Co., Ltd.

1,838.00 -11.59%

4519.T Chugai Pharmaceutical Co., Ltd.

6,806.00 -5.34%

4503.T Astellas Pharma Inc.

2,471.50 -7.52%

U.S. markets closed

Nippon Shinyaku Co., Ltd. (4516.T)

-2.79%

-0.77%

-30.13%

-40.88%

3.50%

-64.32%

253.81%

Nippon Shinyaku Co., Ltd. Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share (GAAP)

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch